Drug Trial Radar · NCT07629336
SAR447971 First-in-human Study
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
122
Planned (sponsor's estimate)
Start
May 26, 2026
Primary completion
Apr 17, 2028
Study completion Apr 17, 2028
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Kymera Therapeutics, Inc.
- First posted
- Jun 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
SAD20411 is a single-center, first-in-human, double-blind, randomized, placebo-controlled, sequential single ascending dose study in healthy male and/or female participants with a pilot food effect investigation. MAD20412 is a single-center, double-blind, randomized, placebo-controlled, sequential multiple ascending dose study in healthy male and/or female participants. MAD24339 is an open-label, sequential multiple ascending dose study in hidradenitis suppurativa (HS) male and/or female participants. Number of participants The total expected number of healthy participants is approximately 102 and the total number of HS participants is expected to be approximately 20. * SAD20411 will enroll up to 54 participants * MAD20412 will enroll up to 48 participants * MAD24339 will enroll up to 20 participants Duration of study The anticipated study duration per participant is up to approximately 10 weeks in SAD20411 and MAD20412, and up to approximately 12 weeks in MAD24339.
Conditions
- Hidradenitis
- Healthy Volunteers
Interventions
SAR447971Drug
Pharmaceutical form: Tablet Route of administration: Oral
PlaceboDrug
Pharmaceutical form: Tablet Route of administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- SAD20411: Incidence of treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 15
- SAD20411: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Time frame: Day 1 to Day 15
- SAD20411: Incidence of clinically significant abnormalities in vital signsTime frame: Day 1 to Day 15
- SAD20411: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Time frame: Day 1 to Day 15
- MAD20412: Incidence of treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 29
- MAD20412: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Time frame: Day 1 to Day 29
- MAD20412: Incidence of clinically significant abnormalities in vital signsTime frame: Day 1 to Day 29
- MAD20412: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Time frame: Day 1 to Day 29
- MAD24339: Incidence of treatment emergent adverse events (TEAEs)Time frame: Day 1 to Day 42
- MAD24339: Incidence of clinically significant abnormalities in clinical laboratory evaluations (hematology, biochemistry, coagulation, urinalysis)Time frame: Day 1 to Day 42
- MAD24339: Incidence of clinically significant abnormalities in vital signsTime frame: Day 1 to Day 42
- MAD24339: Incidence of clinically significant abnormalities in ECG (heart rate, PR, QRS, QT, QTcF)Time frame: Day 1 to Day 42
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Investigational Site Number: 5280001
Leiden, Netherlands · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.